We are live on ! Find out more
FCMI

Foresite Capital Management II Portfolio holdings

AUM $29.2M
1-Year Est. Return 44.84%
This Fund
S&P 500
This Quarter Est. Return
+37.75%
1 Year Est. Return
+44.84%
3 Year Est. Return
-66.21%
5 Year Est. Return
-36.36%
10 Year Est. Return
–
AUM
$460M
AUM Growth
-$49.1M
Cap. Flow
-$201M
Cap. Flow %
-43.66%
Top 10 Hldgs %
100%
Holding
4
New
1
Increased
1
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
NVAX icon
Novavax
NVAX
+$8.21M
2
XLRN
Acceleron Pharma
XLRN
+$1.11M

Top Sells

Rank Stock Value
1
TXG icon
10x Genomics
TXG
+$210M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TXG icon
1
10x Genomics
TXG
$5.87B
$437M 95.05%
3,503,528
-2,000,000
-36% -$210M
EPZM
2
DELISTED
Epizyme, Inc
EPZM
$10.3M 2.24%
862,402
– –
NVAX icon
3
Novavax
NVAX
$1.23B
$7.3M 1.59%
+67,373
New +$8.21M
XLRN
4
DELISTED
Acceleron Pharma
XLRN
$5.16M 1.12%
45,884
+11,100
+32% +$1.11M

Similar funds

AG
Appleton Group Appleton, Wisconsin $28.6M AUM 32.21% 1-Year Est. Return
SAM
Sandbar Asset Management London, United Kingdom $30.5M AUM 46.07% 1-Year Est. Return
AC
Amia Capital London, United Kingdom $32.1M AUM 0.56% 1-Year Est. Return
QI
Qualcomm Inc San Diego, California $32.1M AUM 5.35% 1-Year Est. Return
TAAM
Top Ace Asset Management Hong Kong $25.3M AUM 23.27% 1-Year Est. Return
NAM
Nationwide Asset Management Columbus, Ohio $25.1M AUM 13.37% 1-Year Est. Return
MSKCC
Memorial Sloan Kettering Cancer Center New York $24.6M AUM 10.16% 1-Year Est. Return
BRC
Bishop Rock Capital New York $24.3M AUM 20.73% 1-Year Est. Return

Foresite Capital Management II's Q3 2020 Portfolio in Review

As of Q3 2020, Foresite Capital Management II held 4 positions worth $460M, down 9.7% from $509M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Foresite Capital Management II withdrew a net $201M in Q3 2020, reducing 1 holding. Its largest reduction was 10x Genomics, cutting an estimated $210M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Foresite Capital Management II opened a new position in Novavax worth $7.3M.

  • Foresite Capital Management II's largest Q3 2020 buy was Novavax: 67,373 shares worth $7.3M.
  • Foresite Capital Management II added most to Acceleron Pharma in Q3 2020, an estimated $1.11M increase.
  • Foresite Capital Management II's biggest Q3 2020 reduction was 10x Genomics, cutting an estimated $210M.
  • Foresite Capital Management II's ten largest holdings make up 100% of its $460M portfolio in Q3 2020.
  • Foresite Capital Management II opened 1 new position and closed 0 in Q3 2020.
  • Foresite Capital Management II's portfolio value fell 9.7% quarter-over-quarter to $460M.

Based on Foresite Capital Management II's 13F filing for Q3 2020, filed 13 Nov 2020.